| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12253-015-9903-1 |
| P698 | PubMed publication ID | 25648439 |
| P2093 | author name string | Qiang Chen | |
| Xin-li Wang | |||
| Xiao-bing Huang | |||
| Dong-ta Zhong | |||
| Meng-xin Lin | |||
| Ri-ping Wu | |||
| Yan-qin Lan | |||
| P2860 | cites work | Cancer statistics, 2009 | Q29547625 |
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer | Q33385128 | ||
| Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). | Q33386875 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 | ||
| A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer | Q36858273 | ||
| New perspectives in the treatment of advanced or metastatic gastric cancer | Q43112721 | ||
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 | ||
| Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. | Q43702441 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group | Q73676552 | ||
| [Pharmacokinetics of S-1] | Q80083603 | ||
| Effect of age on prognosis in patients with gastric cancer | Q83974493 | ||
| P433 | issue | 4 | |
| P921 | main subject | oxaliplatin | Q422327 |
| P304 | page(s) | 867-873 | |
| P577 | publication date | 2015-02-04 | |
| P1433 | published in | Pathology Oncology Research | Q26842743 |
| P1476 | title | Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer | |
| P478 | volume | 21 |
Search more.